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Abstract
This paper briefly outlines the aim, the objectives, the architecture and the main building blocks of 
the ongoing large scale integrating transatlantic research project CHIC (http://chic-vph.eu/).
I. Introduction
The impressive rate of generation of human biological data during the last decades has 
dictated the development of numerous statistical, computational and mathematical methods, 
in order to extract, analyze and exploit the hidden wealth of information. Unquestionably 
systems biology has been established as a key player in this arena. However, despite 
its maturation over the last decade a number of obstacles render it difficult for systems 
biology to be directly exploitable by clinical practice [1]. Recognizing that in most medical 
conditions crucial biological phenomena are manifested at several spatiotemporal scales, 
including scales lying far above the subcellular level - which is traditionally addressed by 
systems biology- researchers have proposed a number of ways to integrate super-cellular 
levels into systems biology approaches. Such initiatives have taken various forms and names 
such as systems physiology [2] systems medicine, multiscale modeling [3] and Virtual 
Physiological Human (VPH).
Cancer in the clinical context dictates the development of integrative hypermodels consisting 
of simpler and more manageable constituent component models which may already be 
available. Nevertheless, in order for models generally developed by different modellers or 
modelling groups to be reusable, there are a number of prerequisites that have to be satisfied. 
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Models should be robust, reproduceable and interoperable. This implies that standardization 
of model description and operation is a sine qua non necessity if rational, coherent and 
comprehensive exploitation of the invaluable information hidden within human multiscale 
biological data is envisaged. Responding to this imperative in the context of both the broad 
(VPH) initiative and the paradigmal cancer domain, CHIC proposes the development of 
a suite of tools and services in a secure infrastructure that will support accessibility and 
reusability of VPH mathematical and computational hypermodels. The proposed objective 
is primarily centered around the development of a hypermodelling environment which, 
although will be applicable to the broad VPH space, it will be driven by and originally tested 
in the cancer domain. In order to ensure clinical relevance and foster clinical acceptance 
of hypermodelling in the future, the whole endeavour will in practice be driven by the 
clinical partners of the consortium. Cancer hypermodels to be collaboratively developed 
by the consortium cancer modellers will provide the framework and the testbed for the 
development of the CHIC technologies. Clinical adaptation and partial clinical validation 
[4–5] of hypermodels and hypermodel oncosimulators will be undertaken.
II. Aim
The CHIC proposal aims at developing cutting edge ICT tools, services and secure 
infrastructure to foster the development of elaborate and reusable integrative models 
(hypermodels) and larger repositories so as to demonstrate benefits of having both the 
multiscale data and the correponding models readily available. Although the broader VPH 
domain is the primary target of the hypermodelling infrastructure to be developed by CHIC, 
the primary application domain will be cancer and in silico oncology.
In the mid and long term CHIC aims to pave the way for reliable in silico clinical 
trials, lying at the heart of the vision of in silico medicine, and subsequently for patient 
individualized treatment optimization based on in silico experimentation [4–5].
III. Objectives
CHIC proposes the development of clinical trial driven tools, services and secure 
infrastructure that will support the creation of multiscale cancer hyper-models (integrative 
models). The latter are defined as choreographies of component models, each one describing 
a biological process at a characteristic spatiotemporal scale, and of relation models/
metamodels defining the relations across scales. Integrative models can become component 
models for other integrative models. The development of a secure hypermodelling 
infrastructure consisting primarily of a hypermodelling editor and a hypermodelling 
execution environment is a central generic VPH geared objective of CHIC.
In order to render models developed by different modellers semantically interoperable, 
an infrastructure for semantic metadata management along with tools and services for 
ontology-based annotations will be developed. Existing approaches such as the one 
developed by the EC funded RICORDO project will be exploited and extended. Facilitated 
operations will range from automated dataset matching to model merging and managing 
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complex simulation workflows. In this way standardization of cancer model and data 
annotation allowing multiscale hypermodelling will be fostered.
The following entities will also be developed: a hypermodel repository, a hypermodel-driven 
clinical data repository, a distributed metadata repository and an in silico trial repository for 
the storage of executed simulation scenarios, an image processing toolkit, a visualization 
toolkit and cloud and virtualization services.
In order to ensure that the entire project will be clinically driven and clinically 
oriented, three concrete clinical trials/studies will be adopted and addressed. They concern 
nephroblastoma treated by combined chemotherapy, glioblastoma treated by immunotherapy 
in combination with chemotherapy and radiotherapy and non-small cell lung cancer treated 
by a combination of chemotherapy and radiotherapy.
The multiscale data generated by these trials/studies will be exploited so as to both drive 
the development of a number of integrative multiscale cancer models (hypermodels) and 
hypermodel oncosimulators and clinically adapt and partly validate them.
The whole process will be supported by the technological tools, services and infrastructure 
to be developed and will serve as a paradigm of applicability and usability of the latter. 
Additional available multiscale data concerning colon and prostate cancer will be exploited 
in a similar way. The participation of five prominent multiscale cancer modelling groups 
from both EU and the US covering all spatiotemporal scales (from the molecular up to 
the organism and from nsecs up to years) and all the fundamental biological processes of 
cancer as well as some aspects of the treatment response of normal tissues will ensure a 
comprehensive coverage of the domain of cancer. The latter refers to both the process of 
annotating component models and hypermodels as well as pertinent multiscale data and the 
development of exemplary clinically driven and clinically validatable hypermodels.
This is expected to considerably advance the exploitation of both existing models and 
models to be developed in the future. An integrative platform dictated by the IT architecture 
of the project will provide access to all hypermodelling tools and services to be developed. 
Apart from the tools addressing semantic interoperability, a number of data pre-processing 
tools, services and resources will be developed and/or made available. These will include 
inter alia image segmentation, three-dimensional reconstruction, several forms of data and 
model prediction visualization and cloud computing.
The legal and ethical aspects of patients’ data handling will be addressed by a workpackage 
dealing with both the legal and the IT aspects of data anonymization and pseudonymization, 
patient’s consent etc. The same work package will also address the intellectual rights issues 
arising from the amalgamation of component models potentially developed by different 
modellers in order to construct integrative models.
The dissemination and exploitation of the CHIC proposal will target all stakeholders, 
namely clinicians, fundamental science researchers, IT specialists and engineers, industry 
and patients. Similarly, the project is expected to have a significant impact on all the 
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corresponding domains. More precisely, CHIC aspires to make a breakthrough in multiscale 
cancer modelling through greatly facilitating multi-modeller cancer hypermodelling and its 
clinical adaptation and validation. Standardization of model description and model “fusion” 
will be two of the core means to achieve this goal. The creation of such elaborate and 
refined hypermodels is expected to sharply accelerate the clinical translation of multiscale 
cancer models and oncosimulators following their prospective clinical validation (in silico 
oncology). Addressing intellectual property issues in a multi modeller setting will foster the 
community spirit in the VPH domain.
IV. Architecture and MAIN Building Blocks of CHIC
CHIC will develop a variety of tools and repositories that will assist the researcher in 
searching and retrieving models and data, composing and saving hypermodels, executing 
models and hypermodels and last but not least validating the outcome of the simulations 
(Fig. 1).
The core reference point for the users will be the CHIC portal. All the components of CHIC 
will reside under the “umbrella” of the security framework that will deal with the issues of 
secure and safe storing, acquisition and sharing of models and data.
Four individual repositories will be implemented in CHIC.
• A model repository that will store the multiscale models, the complimentary 
tools and modules that will be needed in order to construct hypermodels 
and the hypermodels themselves. In the model repository will also reside the 
visualization and image processing tools that will be developed in CHIC.
• A data repository that will store the heterogeneous multiscale data coming from 
clinical environment (clinical trials etc.). Especially for the storage of “sensitive” 
patient-specific data a special pseudo-anonymization/anonymization procedure 
will be followed in compliance with the legal and ethical framework. Due to 
legal limitations, the CHIC repositories, especially the ones that are dealing with 
patient data, will be implemented so as to be easily deployable in local or private 
cloud infrastructures of medical, educational and research institutions.
• A metadata repository that will store the machine-readable documentation 
material that will semantically represent both models and data.
• An in silico trial repository which will store the input and output of the in silico 
simulations along with the complete profile of each simulation, including the 
model/hypermodel used in the simulation and its version, the model/hypermodel 
configuration parameters etc.
The users will upload their models and the complimentary tools in the model repository. 
In addition the user will use the model annotation framework to add semantic information 
to his/her models and data. This information will be used later on by the hypermodelling 
framework in order to construct and execute hypermodels (Fig.2).
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The composition and execution of hypermodels will be done by the Hypermodelling 
Framework. This will consist of the Hypermodelling Editor and the Hypermodel 
Executional Framework. The Hypermodelling Editor will communicate with the model 
and metadata repositories and will guide the user in easily and effectively constructing 
hypermodels (Fig.3) by
• exposing information about existence and availability of models,
• presenting interconnection possibilities,
• indicating the model/modules that need to be developed in order to fill in the 
gaps,
• visually constructing the hypermodels, provided that all needed components are 
available, either as implemented models/modules or as a “ to be implemented” 
dummy black boxes.
The Hypermodel Executional Framework will communicate with the model, the metadata 
and the data repository, in order to retrieve the relevant information to be used in the 
simulation (in silico trial). The outcome of the execution will be send to the in silico trial 
repository for persistent storage. The user will be able to retrieve the results of a simulation 
from the in silico trials repository (Fig.4).
The CHIC image processing tools will be used in the preprocessing of imaging data in order 
to be prepared for usage in the simulations. The results of the simulations will use the CHIC 
visualization tools in order to be presented to the user.
Fig.5 shows the gross overall CHIC architecture from a clinical study and trial centered 
perspective.
The Hypermodel Oncosimulator is an extension of the notion and the system of the 
original Oncosimulator [4–5] so as to make use of cancer and normal tissue hypermodels. 
The (hypermodel) Oncosimulator is at the same time a concept of multilevel integrative 
cancer biology, a complex algorithmic construct, a biomedical engineering system and 
eventually in the future a clinical tool which primarily aims at supporting the clinician in 
the process of optimizing cancer treatment in the patient individualized context through 
conducting experiments in silico i.e. on the computer. Additionally it is a platform 
for simulating, investigating, better understanding and exploring the natural phenomenon 
of cancer, supporting the design and interpretation of clinicogenomic trials and finally 
training doctors, researchers and interested patients alike. A synoptic outline of the clinical 
utilization of a specific version of the Oncosimulator, as envisaged to take place following 
an eventually successful completion of its clinical adaptation, optimization and validation 
process is provided in the form of steps (Fig.6).
In this paper a short description of the main technical architecture and components of 
the CHIC project has been provided. Initial successful results (http://chic-vph.eu/) have 
demonstrated that the design of the project is realistic and possesses great potential for the 
semi-automatic development of cancer hypermodels. Since the technologies developed are 
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quite generic, an extension to domains beyond cancer will be an obvious additional outcome 
of the project.
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Main technological components of CHIC directly related to the hypermodelling workflow
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Model and metamodel creation workflow
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Hypermodel and meta-hypermodel creation workflow
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Clinical scenario driven hyper- model development
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The overall CHIC architecture from a clinical study and trial centered perspective
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A synoptic diagram of the hypermodel based Oncosimulator
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